All In Biotech

Drug Trial Radar · NCT04561063

COVID-19 Prophylaxis South Africa (COVER HCW)

A Multi-center, Randomised, Open Label Study of Nitazoxanide (NTZ), or Sofosbuvir and Daclatasvir (SOF/DCV), Compared to no Pharmacological Intervention for the Prevention of COVID-19 Disease in Healthcare Workers and Inner City Inhabitants at High Risk of Exposure to SARS-CoV-2

Last checked: Nov 19, 2026Latest source record: Jun 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,950 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,950

Actual

Start

Dec 8, 2020

Primary completion

Feb 28, 2022

Study completion Feb 28, 2022

Sponsor

Lead sponsor
University of Witwatersrand, South AfricaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomised, multi-center, open label, adaptive, exploratory trial to assess the efficacy of two different drug regimens in terms of preventing symptomatic COVID-19 disease in healthcare workers at high risk of exposure to SARS-CoV-2. The trial will compare two different experimental medication arms to the control arm comprising the use of standard personal protective equipment (PPE) with no additional pharmacological intervention.

Conditions

  • Covid19
  • SARS-CoV Infection

Interventions

  • NitazoxanideDrug

    Nitozoxanide 1 tablet (500 mg) taken 12-hourly with food for the first week, followed by 2 tablets (1000 mg) taken 12-hourly with food thereafter. (Participants that fail to tolerated the 1000 mg 12-hourly dose may revert back to the lower dose.)

  • Sofosbuvir/DaclatasvirDrug

    Sofosbuvir/daclatasvir 400mg/60 mg sofosbuvir/daclatasvir fixed dose combination 1 tablet daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of SARS-CoV-2 infectionsTime frame: 6 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Charlotte Maxeke Johannesburg Academic Hospital

    Johannesburg, Gauteng, South Africa

  • Sunnyside Office Park

    Johannesburg, Gauteng, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.